ReviewPharmaceuticals (Basel, Switzerland)2018
The Functional Versatility of Transferrin Receptor 2 and Its Therapeutic Value.
Review in Pharmaceuticals (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Immunohistochemical investigation of transferrin receptor 2 (TFR2) immunoreactivity in patients with cutaneous lichen planus.Irish journal of medical science · 2026Article
- Collection Series "Iron Homeostasis".International journal of molecular sciences · 2025Article
- Transferrin receptors.Experimental & molecular medicine · 2025Review
- Lack of Hfe and TfR2 in Macrophages Impairs Iron Metabolism in the Spleen and the Bone Marrow.International journal of molecular sciences · 2024Article
- Brain Iron Dyshomeostasis and Ferroptosis in Alzheimer's Disease Pathophysiology: Two Faces of the Same Coin.Aging and disease · 2024Review
- Biomarkers in Ovarian Cancer: Towards Personalized Medicine.Proteomes · 2024Review
- Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets.Circulation research · 2023Review
- Inimical impact of high-fat diet on expression of heme oxygenase-1, trace metals content, and associated intestinal histopathology.Toxicology research · 2023Article
- Investigation of Trends in the Research on Transferrin Receptor-Mediated Drug Delivery via a Bibliometric and Thematic Analysis.Pharmaceutics · 2022Review
- Clinical and Molecular Aspects of Iron Metabolism in Failing Myocytes.Life (Basel, Switzerland) · 2022Review
- Activation of the Hepcidin-Ferroportin1 pathway in the brain and astrocytic-neuronal crosstalk to counteract iron dyshomeostasis during aging.Scientific reports · 2022Article
- Genetic variants in promoter region ofGastroenterology report · 2022Article
- Iron-Deficiency in Atopic Diseases: Innate Immune Priming by Allergens and Siderophores.Frontiers in allergy · 2022Review
- Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver.Antioxidants (Basel, Switzerland) · 2021Review
- Transferrin Receptors in Erythropoiesis.International journal of molecular sciences · 2020Review
- Erythropoietin regulation of red blood cell production: from bench to bedside and back.F1000Research · 2020Review
- Iron as Therapeutic Target in Human Diseases.Pharmaceuticals (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron homeostasis is a tightly regulated process in all living organisms because this metal is essential for cellular metabolism, but could be extremely toxic when present in excess. In mammals, there is a complex pathway devoted to iron regulation, whose key protein is hepcidin (Hepc), which is a powerful iron absorption inhibitor mainly produced by the liver. Transferrin receptor 2 (Tfr2) is one of the hepcidin regulators, and mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.